%20and%20Batch%20Production%20Records%20(BPR).png)
Lupin receives tentative approval from US FDA for Revefenacin Inhalation Solution
Global pharma major, Lupin announced that it has received tentative approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Revefenacin Inhalation Solution, 175 mcg/3 mL Unit-Dose Vials.
Lupin’s Revefenacin Inhalation Solution, 175 mcg/3 mL is bioequivalent to Mylan’s Yupelri Inhalation Solution and indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
Revefenacin Inhalation Solution (RLD Yupelri) had estimated annual sales of USD 260.7 million in the US. (IQVIA MAT March 2026).
The post Lupin receives tentative approval from US FDA for Revefenacin Inhalation Solution appeared first on Express Pharma.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
Edusehat
Platform Edukasi Online Untuk Komunitas Kesehatan Agar Mendapatkan Informasi Dan Pengetahuan Terbaru Tentang Kesehatan Dari Nasional Maupun Internasional. ||
An online education platform for the health community to obtain the latest information and knowledge about health from both national and international sources.
